New Study Reveals Safe, Effective Therapy for Active Ulcerative Colitis

New Study Reveals Safe, Effective Therapy for Active Ulcerative Colitis
A new study conducted by an international research team recently revealed that the corticosteroid, beclomethasone dipropionate (BDP), can be successfully employed as a treatment strategy for patients with active mild-to-moderate ulcerative colitis. The study was published in The American Journal of Gastroenterology and is entitled “Oral Prolonged Release Beclomethasone Dipropionate and Prednisone in the Treatment of Active Ulcerative Colitis: Results From a Double-Blind, Randomized, Parallel Group Study.” Ulcerative colitis is a type of chronic inflammatory bowel disease (IBD) characterized by inflammation in the colon, formation of ulcers (tiny open sores), abdominal discomfort and diarrhea with blood. Ulcerative colitis is thought to be the result of an abnormal response by the body's immune system. Prednisone is a synthetic corticosteroid drug that has immunosuppressive properties and is often employed in the treatment of inflammatory conditions such as ulcerative colitis. It can, however, induce significant adverse effects. BDP is a potent corticosteroid drug designed to prevent and control asthma symptoms; it is also licensed for ulcerative colitis treatment in conjunction with 5-aminosalicylates, the first line therapy for achieving and maintaining remission of IBD. In this study, researchers compared the safety and efficacy of BDP to prednisone in 282 patients suffering from active, mild-to-moderate ulcerative colitis not responsive to 5-aminosalicyilic acids. The study was c
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *